載入...
Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines
Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor,...
Na minha lista:
| 發表在: | Mol Pharm |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4783219/ https://ncbi.nlm.nih.gov/pubmed/26824142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.5b00447 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|